Gamida Cell Ltd. - Ordinary Shares (GMDA): Price and Financial Metrics
GMDA Price/Volume Stats
| Current price | $2.29 | 52-week high | $3.66 |
| Prev. close | $2.31 | 52-week low | $0.56 |
| Day low | $2.28 | Volume | 777,381 |
| Day high | $2.36 | Avg. volume | 3,345,541 |
| 50-day MA | $1.54 | Dividend yield | N/A |
| 200-day MA | $1.69 | Market Cap | 170.33M |
GMDA Stock Price Chart Interactive Chart >
Gamida Cell Ltd. - Ordinary Shares (GMDA) Company Bio
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Latest GMDA News From Around the Web
Below are the latest news stories about GAMIDA CELL LTD that investors may wish to consider to help them evaluate GMDA as an investment opportunity.
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare ConferenceBOSTON, May 31, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commercial Officer, will present corporate highlights at the upcoming Jefferies Healthcare Conference on June 8, 2023 at 9:30 a.m. ET. |
Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual MeetingBOSTON, May 31, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that an oral presentation highlighting Gamida Cell’s investigational natural killer (NK) cell therapy candidate GDA-201 will be shared at the International Society for Cell and Gene Therapy (ISCT) 2023 Annual Meeting. The meeting takes place May 31-June 3 in Paris, France. |
Gamida Cell Appoints Terry Coelho as CFOBOSTON, May 22, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the appointment of Terry Coelho as Chief Financial Officer effective immediately. Shai Lankry, who has served as the company’s CFO for the past five years, is stepping down as CFO today and will leave the company June 2. |
Breakeven On The Horizon For Gamida Cell Ltd. (NASDAQ:GMDA)Gamida Cell Ltd. ( NASDAQ:GMDA ) is possibly approaching a major achievement in its business, so we would like to shine... |
Gamida Cell Ltd. (GMDA) Q1 2023 Earnings Call TranscriptGamida Cell Ltd. (GMDA) Q1 2023 Results Conference Call May 15, 2023 04:30 PM ET Company Participants Mike Kuczkowski - Corporate Communications Abbey Jenkins - President and CEO Michele Korfin - COO and Chief Commercial Officer Ronit Simantov - Chief Medical Officer and Scientific Officer Shai Lankry - CFO Conference Call Participants Edward Tenthoff - Piper Sandler Gil Blum - Needham & Company Vernon Bernardino - H.C. Wainwright Mark Breidenbach - Oppenheimer Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to the Gamida Cell’s Conference Call for the First Quarter 2023 Financial Results... |
GMDA Price Returns
| 1-mo | 38.79% |
| 3-mo | 37.13% |
| 6-mo | 77.52% |
| 1-year | 5.05% |
| 3-year | -52.88% |
| 5-year | N/A |
| YTD | 77.52% |
| 2022 | -49.21% |
| 2021 | -69.73% |
| 2020 | 95.12% |
| 2019 | -56.74% |
| 2018 | N/A |
Loading social stream, please wait...